Details for New Drug Application (NDA): 021064

✉ Email this page to a colleague

NDA 021064 describes DEFINITY RT, which is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the DEFINITY RT profile page.

The generic ingredient in DEFINITY RT is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.

Summary for 021064

Tradename:	DEFINITY RT
Applicant:	Lantheus Medcl
Ingredient:	perflutren
Patents:	10

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 021064

Generic Entry Date for 021064^: ⤷ Subscribe* Constraining patent/regulatory exclusivity: 5,527,521 Dosage: INJECTABLE;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 021064

Mechanism of Action	Ultrasound Contrast Activity

Suppliers and Packaging for NDA: 021064

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064	NDA	Lantheus Medical Imaging, Inc.	11994-011	11994-011-01	1 VIAL, GLASS in 1 CARTON (11994-011-01) / 1.5 mL in 1 VIAL, GLASS
DEFINITY RT	perflutren	INJECTABLE;INTRAVENOUS	021064	NDA	Lantheus Medical Imaging, Inc.	11994-011	11994-011-01	1 VIAL, GLASS in 1 CARTON (11994-011-01) / 1.5 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	13.04MG/2ML (6.52MG/ML)
Approval Date:	Jul 31, 2001	TE:		RLD:	Yes
Patent:	10,583,207	Patent Expiration:	Dec 28, 2035	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
Patent:	10,583,208	Patent Expiration:	Mar 16, 2037	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
Patent:	10,588,988	Patent Expiration:	May 4, 2037	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Expired US Patents for NDA 021064

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001	8,685,441	⤷ Subscribe
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001	6,033,645	⤷ Subscribe
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001	8,658,205	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.